John Clarke
Non-Executive Chairman
John Clarke became Chairman of Futura on 1 February 2012. He has extensive experience of the healthcare sector, having worked at GSK for more than 35 years. In 2006 he was appointed President of GSK Consumer Healthcare, a position from which he recently stepped down in October 2011. Under his leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. It achieved 60% sales growth between 2006 and 2010, when it recorded a turnover of £5 billion. He is currently also a Non-Executive Director of Provexis plc and a Director of the US-based Consumer Healthcare Products Association.
James Barder
Chief Executive
James Barder joined the Company as Chief Executive in June 2001. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for all shareholder and investor relations matters and leads licensing and distribution negotiations and new product development activities. He first became involved with the Group as an investor in 1997 and has been a Director of the subsidiary since 1998. Prior to becoming Chief Executive, he was Managing Director of Aon Capital Markets Limited. He has predominantly worked in the fields of insurance and finance including firms he founded and co-owned and is also a Non-Executive Director of Lorega Limited.
David Davies, BSc (Hons), MBA
Chief Development Officer
David Davies joined the Board in September 2001. He is responsible for all product development programmes for the Group. Prior to joining the Company, he was Director of Project Management at Clintrials Research Ltd. He has over 25 years of experience of pharmaceutical and healthcare product development, within pharmaceutical companies and global contract clinical research organisations. Previous employers include Porton Down, Glaxo Group Research, Wellcome Research Ltd, Zambon Limited and PPD Pharmaco Ltd. He is a Director and Company Secretary of Pharmaceutical Contract Management Limited and is also Company Secretary of the registered charity Ordinary 2 Extraordinary Limited.
Derek Martin, BSc (Hons), ACA
Finance Director
Company Secretary
Derek Martin joined the Board as Finance Director in September 2008. He oversees the Group's finance function and also its compliance procedures. He qualified as a Chartered Accountant in 1984 and has over 20 years of experience in a variety of senior accounting roles in a diverse range of industries including software, retail, telecoms and media. Recent roles have included positions of Financial Controller at Links of London, a retail jeweller, and Entuity Limited, a US software development company.
Jonathan Freeman, BA (Hons), MBA
Senior Independent Non-Executive Director and
Chairman of Remuneration Committee and Audit Committee
Jonathan Freeman joined the Board in July 2003 and was appointed Senior Independent Non-Executive Director in November 2003. As well as chairing the Audit Committee and the Remuneration Committee, he is also a member of the Nominations Committee. He provides guidance on City regulatory matters, corporate finance and investor relations. He has worked in the UK financial services sector for over 20 years with previous roles including: Director of Beeson Gregory (now Evolution Securities), Director of a number of quoted investment companies and, most recently, Group Chief Executive Officer of Syndicate Asset Management plc. He is also currently a Non-Executive Director of Photonstar LED Group Limited, where he also chairs the Audit Committee, and a Director of CMS Corporate Consultants Limited.
Lisa Arnold
Independent Non-Executive Director
Chair of Nominations Committee
Lisa Arnold joined the Board in March 2008. As well as chairing the Nominations Committee, she is also a member of the Remuneration Committee and the Audit Committee. She has extensive experience of the investment and healthcare sectors. She worked in the investment banking industry from 1984 to 2001, holding senior positions including Sector Head of Pharmaceuticals and Healthcare at UBS and Commerzbank. Since 2001, she has worked in consultancy and non-executive roles predominantly in the pensions, healthcare and technology sectors. She is currently a Non-Executive Director of the UK's Medicines and Healthcare products Regulatory Agency ("MHRA"), where she also chairs the Risk & Audit Committee, and an adviser to the Allied Domecq Pension Funds and the Kraft UK Pension Fund (Trustees).
Dr. Bill Potter, PhD
Chief Scientific Officer
Dr Bill Potter stepped down as Chairman on 31 January 2012 and is no longer a Director of the Company but he continues to provide advice and expertise to the Board on a consultancy basis on product development matters in his role as Chief Scientific Officer, bringing to bear his considerable experience gained over 30 years in R&D including bringing a wide range of new medical device products to market. He has extensive knowledge of worldwide regulatory procedures, intellectual property issues and licensing. He previously worked at London International Group plc, including seven years as Group Scientific Affairs Director and at Smith & Nephew plc.